Your browser doesn't support javascript.
loading
Efficacy and safety of Morinda officinalis oligosaccharide capsules for depressive disorder: a systematic review and meta-analysis
Du, Yun; Zheng, Qin; Ou, Zheng-Hang; Cao, Yu-Jia; Su, Xiao-Peng; Li, Chunbo; Qu, Miao.
  • Du, Yun; Capital Medical University. Neurology Department, Xuan Wu Hospital. CN
  • Zheng, Qin; Beijing University of Chinese Medicine. Neurology Department, Third Affiliated Hospital. CN
  • Ou, Zheng-Hang; Beijing University of Chinese Medicine. Neurology Department, Third Affiliated Hospital. CN
  • Cao, Yu-Jia; Beijing University of Chinese Medicine. Neurology Department, Third Affiliated Hospital. CN
  • Su, Xiao-Peng; Beijing University of Chinese Medicine. Neurology Department, Third Affiliated Hospital. CN
  • Li, Chunbo; Shanghai Jiao Tong University School of Medicine. Shanghai Mental Health. Shanghai Key Laboratory of Psychotic Disorders. CN
  • Qu, Miao; Capital Medical University. Neurology Department, Xuan Wu Hospital. CN
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 43(3): 306-313, May-June 2021. tab, graf
Article in English | LILACS | ID: biblio-1249200
ABSTRACT

Objective:

To evaluate the efficacy and safety of Morinda officinalis oligosaccharide (MOO) capsules for depressive disorder.

Methods:

Eight electronic databases were searched for relevant studies from inception to April 19, 2020. Randomized controlled trials comparing MOO capsules with antidepressants were included. Data analysis was conducted using Review Manager 5.3 software. The risk of bias was assessed using the Cochrane Risk of Bias Tool, and the quality of the studies was evaluated by two researchers using the Grading of Recommendation, Assessment, Development and Evaluations (GRADE) software.

Results:

Seven studies involving 1,384 participants were included in this study. The effect of MOO capsules for moderate depressive disorder was not different from that of antidepressants (risk ratio [RR] = 0.99, 95%CI 0.92-1.06). Regarding adverse events, no significant difference was found between MOO capsules and antidepressants (RR = 0.84, 95%CI 0.65-1.07). In addition, the quality of evidence related to these adverse events was rated as low.

Conclusion:

This systematic review suggests that the efficacy of MOO capsules in the treatment of mild to moderate depression is not inferior to that of conventional antidepressants, which may provide a new direction for clinical alternative selection of antidepressants. However, more high-quality research and detailed assessments are needed.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Morinda / Depressive Disorder Type of study: Controlled clinical trial / Practice guideline / Systematic reviews Limits: Humans Language: English Journal: Braz. J. Psychiatry (São Paulo, 1999, Impr.) Journal subject: Psychiatry Year: 2021 Type: Article Affiliation country: China Institution/Affiliation country: Beijing University of Chinese Medicine/CN / Capital Medical University/CN / Shanghai Jiao Tong University School of Medicine/CN

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Morinda / Depressive Disorder Type of study: Controlled clinical trial / Practice guideline / Systematic reviews Limits: Humans Language: English Journal: Braz. J. Psychiatry (São Paulo, 1999, Impr.) Journal subject: Psychiatry Year: 2021 Type: Article Affiliation country: China Institution/Affiliation country: Beijing University of Chinese Medicine/CN / Capital Medical University/CN / Shanghai Jiao Tong University School of Medicine/CN